Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.
Location: United States, Massachusetts, Waltham
Employees: 11-50
Total raised: $97M
Founded date: 2019
Investors 9
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.08.2021 | Series B | $58M | - |
| 21.11.2019 | Series A | $39M | - |
Mentions in press and media 16
| Date | Title | Description |
| 24.06.2026 | Tarek Samad appointed EVP, Head of Research & Development at Lundbeck | VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Te... |
| 19.08.2021 | Daily funding roundup - August 19th, 2021 | Postman raised $225M, MobileCoin secures $66M, One landed $40M; Rapid Robotics picks up $36.7M Postman: Postman is a San Francisco-based collaboration platform for API development. Postman has raised $225 million in Series D funding led by ... |
| 19.08.2021 | Immunitas Therapeutics Closes $58M in Series B Financing | Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing. The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta... |
| 18.08.2021 | An important takeaway from Maven Clinic’s $1 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How Optimizely is improving the marketer experience From Optimizely The venture capi... |
| 18.08.2021 | An important takeaway from Maven Clinic’s $1 billion valuation | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How one company is leading in computer vision technology From Telus International Th... |
| 18.08.2021 | Bayer, Novartis-backed Immunitas secures $58M series B to push new checkpoint inhibitors past blockade Age-Appropriate Formulation Development for Pediatric Trials-Challenges and Considerations | Initially backed by Novartis and Bayer's venture arms, immuno-oncology biotech Immunitas has secured another $58 million to push a new class of checkpoint inhibitors on to the next stop. The lead asset from the company's single-cell sequenc... |
| 18.08.2021 | Immunitas Therapeutics Scores $58M Series B | WALTHAM, MA, Immunitas Therapeutics, a biotechnology company, announced $58M in a Series B funding led by Agent Capital. >> Click here for more funding data on Immunitas Therapeutics >> To export Immunitas Therapeutics fundi... |
| 18.08.2021 | Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline | - |
| 18.08.2021 | Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases | |
| 18.08.2021 | Bayer, Novartis-backed Immunitas secures $58M series B to push new checkpoint inhibitors past blockade | Initially backed by Novartis and Bayer's venture arms, immuno-oncology biotech Immunitas has secured another $58 million to push a new class of checkpoint inhibitors on to the next stop. Immunitas is attempting to tackle the hurdles traditi... |
Show more